Anixa Biosciences completes enrollment in Phase 1 trial of breast cancer vaccine

Anixa Biosciences (ANIX) announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is also being developed in partnership with Cleveland Clinic and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense. The final patient visits are scheduled for August 2025. Once completed, the final study report will be submitted to the Department of Defense.